| abstract |
The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and retargeting to specific target cells. Additionally, the invention relates to polynucleotides encoding such bispecific antigen binding molecules, as well as vectors and host cells comprising such polynucleotides. The invention further relates to methods of making the bispecific antigen binding molecules of the invention, and methods of using the bispecific antigen binding molecules to treat diseases. |